Humoral SPARC/osteonectin protein in plasma cell dyscrasias

October 2005
Croatian Medical Journal;2005, Vol. 46 Issue 5, p862
Academic Journal
Presents an abstract of a study that determined secreted protein acidic and rich in cysteine (SPARC)/osteonectin in patients with multiple myeloma and related diseases in order to assess the role of SPARC as a possible marker of tumor burden and disease progression.


Related Articles

  • Auer rod-like inclusions in plasma cells in multiple myeloma. Wai Khoon Ho; Daniela Zantomio // Journal of Clinical Pathology;Jun2014, Vol. 67 Issue 6, p547 

    The article presents a case study of a female patient who presented to physicians with bone pain. A discussion of diagnostic testing which was conducted on the patient, and resulted in her receiving a diagnosis of multiple myeloma with Auer rod-like inclusions in her plasma cells, is presented.

  • PET/CT studies of multiple myeloma using F-FDG and F-NaF: comparison of distribution patterns and tracers' pharmacokinetics. Sachpekidis, Christos; Goldschmidt, Hartmut; Hose, Dirk; Pan, Leyun; Cheng, Caixia; Kopka, Klaus; Haberkorn, Uwe; Dimitrakopoulou-Strauss, Antonia // European Journal of Nuclear Medicine & Molecular Imaging;Jul2014, Vol. 41 Issue 7, p1343 

    Objective: The aim of this prospective study is to evaluate the combined use of fluorine-18 fluorodeoxyglucose ( F-FDG) and fluorine-18 sodium fluoride ( F-NaF) PET/CT in the skeletal assessment of patients with multiple myeloma (MM) and to compare the efficacy of these two PET tracers regarding...

  • In vivo inhibition of cysteine proteinases delays the onset of growth of human pancreatic cancer explants. Van Noorden, C J F; Jonges, T G N; Meade-Tollin, L C; Smith, R E; Koehler, A // British Journal of Cancer;2/15/2000, Vol. 82 Issue 4, p931 

    An animal model was used to study the effects of oral treatment with a small molecular selective inhibitor of cysteine proteinases, Z-Phe-Arg-fluoromethylketone (Z-Phe-Arg-FMK) on primary tumour development. Poorly differentiated rapidly growing and moderately differentiated slowly growing human...

  • BY THE NUMBERS.  // Hem/Onc Today;7/10/2014, Vol. 15 Issue 13, p1 

    A chart is presented that offers information about the survival rate of patients with newly diagnosed multiple myeloma.

  • DURIE-SALMON SYSTEM AND INTERNATIONAL STAGING SYSTEM IN DE NOVO MYELOMA PATIENTS. Burazerović, Lejla; Berbić-Fazlagić, Jasmina; Jamaković, Mesud // Medical Journal;apr-jun2013, Vol. 19 Issue 2, p145 

    Multiple myeloma is a cancer of plasma cells. According to available registration of the patients from Clinic of Hematology Clinical Center University of Sarajevo, there are approximately 20 new cases of myeloma patients per year at this Clinic. There are several systems in use that characterize...

  • Acquired Pure Red Cell Aplasia in patients with plasma cell neoplasm and long term remission with bortezomib therapy. Sarathy, Kiran S.; Ramakrishna, Raj; Baig, Waqas W.; Manoharan, Arumugum // Journal of Hematological Malignancies;Jun2013, Vol. 3 Issue 2, p37 

    We report two cases of Pure Red Cell Aplasia (PRCA) associated with plasma cell dyscrasia. The first case is of an elderly woman with PRCA and light chain disease (LCD)/multiple myeloma (MM). She received multiple blood transfusions and was refractory to conventional therapies. Subsequent...

  • Mandibular Plasmacytoma of Jaw - A Case Report. KAMAL, MEET; KAUR, PARWINDER; GUPTA, RAKHI; GUPTA, SHALLY; SINGH, SIMRANJIT // Journal of Clinical & Diagnostic Research;Aug2014, Vol. 8 Issue 8, p20 

    The plasma cell neoplasm may present as Extramedullary Plasmacytoma (EMP) in soft tissues in bone as a Solitary Plasmacytoma of bone (SPB) or as a part of multi focal disseminated disease Multiple Myeloma (MM). The majority of 80% occurs in head and neck region. In our case, a 62-year-old male...

  • Relapse of Multiple Myeloma Presenting as Extramedullary Plasmacytomas in Multiple Organs. Köse, Murat; Buraniqi, Ersida; Akpinar, Timur Selçuk; Kayacan, Seyit Mehmet; Tükek, Tufan // Case Reports in Hematology;1/28/2015, Vol. 2015, p1 

    Multiple myeloma is a neoplastic plasma cell disorder. It is characterized by collections of abnormal plasma cells accumulating in the bone marrow, where they interfere with the production of normal blood cells. It usually presents as a multisystemic involvement, whose symptoms and signs vary...

  • Atypical polyarthritis as a major manifestation of light chain disease. Landuyt, Kristel; Starmans, Mirian; Peeters, Ralph; Jie, Kon-Siong // Annals of Hematology;Oct2012, Vol. 91 Issue 10, p1653 

    The article discusses systemic light chain amyloidosis (AL amyloisodis) which could be appeared in patients suffering from known plasma cell disorder. It mentions that different types of rheumatic symptoms produced in a patient suffering from smouldering multiple myeloma (SMM) by amyloid...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics